Johnson & Johnson's $8.3 million defeat in a U.S. jury trial over its ASR metal-on-metal hip implant could force it to settle a massive class action lawsuit in Australia over the same product.
Johnson & Johnson is recalling a model of its market-leading LifeScan glucose meters, warning that the devices shut down when confronted with dangerously high blood sugar levels.
South Carolina Circuit Judge Roger Couch took a particularly creative approach when he levied a $327 million penalty against Johnson & Johnson in the state's Risperdal case.
As if 8,000-plus lawsuits alleging faulty all metal helps weren't enough, Johnson & Johnson/DePuy data from an Illinois hospital suggests that repeat surgeries for patients dealing with the implants keep rising.
The logistics of getting drugs delivered in underdeveloped countries can be tricky. Many companies turn to partners with the expertise that can help them navigate the import laws and distribution obstacles that those countries present.
Add up the top-line R&D spending for the top 10 pharma companies in the world and you'd think that nothing had changed from 2011 to 2012. But you'd be very wrong. Big Pharma's heavy hitters in R&D have a wildly mixed record in a fast-changing field. It will be an interesting year ahead. Here's a look at last year's results, and an analysis of where they point. Read the report >>
A Johnson & Johnson executive testified that the company recalled its all-metal hip replacements because they didn't meet "clinical expectations," not because they were defective, but that doesn't quite jibe with internal documents.
The question isn't why Johnson & Johnson CEO Alex Gorsky took a 10% hit to his incentive pay. It's why Chairman William Weldon didn't suffer a bigger cut in his pay.
Johnson & Johnson has prominently planted its R&D flag in London. Today the giant pharma company officially opened up its new innovation center in the U.K., one of four scientific and business development outposts around the world charged with building J&J's ties to the biotech industry and academia as it fosters new development deals.
Johnson & Johnson's Cordis has snatched up a New Jersey maker of self-expanding, flexible stents, with the idea of expanding its own offerings in the technology to treat peripheral artery disease.